Exhibit 16.1

                              [BioMarin Letterhead]


June 11, 2002

Arthur Andersen LLP
101 2nd St., Suite 1100
San Francisco, CA 94105
Attn: Richard J. Blumenfeld

Gentlemen:

This is to inform you that BioMarin Pharmaceutical Inc. will no longer require
the services of Arthur Andersen LLP. Our decision is based upon thorough
consideration given to our current and future business needs.

A representative from KPMG LLC will be contacting you in the next few days to
complete inquiries normal under the circumstances. In addition, please make
arrangements to allow KPMG LLP access to your work papers related to your
examinations of BioMarin's financial statements for the years ended December
31, 2001 and 2000, as well as tax work for those periods.

Please also send a letter to the Securities and Exchange Commission with a copy
to BioMarin Pharmaceutical regarding the disclosure in Item 4 of Form 8-K
relating to the change of independent accountants, a copy of which is attached
for your review.

                                            Sincerely,
                                            BioMarin Pharmaceutical Inc.

                                            /s/ Fredric D. Price
                                            ----------------------------
                                            Fredric D. Price
                                            Chairman and Chief Executive Officer